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NOTES AND COMMENTS 
Viral and atypical pathogens as causes of type 1 acute 
exacerbations of chronic bronchitis 
Clirz Microbiol Infect 1997; 3: 513-514 
Considerable controversy exists regarding the role of 
antibiotics in managing exacerbations of chronic 
obstructive pulmonary disease (COPD). Both viruses 
and bacteria are involved in its pathogenesis. There 
have been many trials to determine the value of anti- 
biotic treatment in acute exacerbations, but most can 
be criticized because of patient selection criteria, lack 
of controls, inappropriate analysis and subjective assess- 
ments [ 1 ]. One placebo-controlled landmark study by 
Anthonisen et a1 [2] showed that antibiotic therapy 
shortened the duration of the exacerbation and pre- 
vented deterioration, especially in the severest type 1 
(worsening dyspnea, increased sputum volume and 
purulence) exacerbation. Moreover, a recently published 
meta-analysis on studies using an antibiotic in the 
treatment and a placebo in the control group suggested 
a small but statistically significant improvement due to 
antibiotic therapy in patients with exacerbations of 
COPD [3]. 
In an editorial in the Lancet [I] after Anthonisen’s 
study it was, however, concluded that the question of 
the need for antibiotic treatment in exacerbations of 
COPD still remained unanswered, especially because 
no assessment of the causative microorganisms was 
made and because, on clinical grounds alone, one is 
unable to do so [l]. 
In the last five years we have carried out four 
studies in patients with acute exacerbations of chronic 
bronchitis in collaboration with chest physicians in 
several hospitals in The Netherlands (Table 1) [4-7). 
The definitions of the American Thoracic Society 
for chronic bronchitis were used. In all studies, only 
patients (357) with the severest form (type 1)  of 
exacerbations according to Anthonisen et a1 were 
included. The mean ages of patients were between 
55 and 65 years. Patients with a pneumonia were 
excluded from this analysis. Following collection of 
purulent sputum for bacterial cultures, blood samples 
were obtained on the first and the third visit (day 
12-16) from 305 of them for serologic determination. 
Antibodies against respiratory pathogens such as 
influenza viruses A and B, parainfluenza viruses 1-4, 
respiratory syncytial virus, adenovirus, Chlamydia psittaci, 
Mycoplasma pneumotziae, Chlamydia pntrumoniae, Legionella 
pneumoplzila and Coxiella burnetii were determined. Tests 
were done by a complement-fixation assay, Chlamydia 
(genus-specific enzyme inmiunoassay) and L. pnetcrrzo- 
phila (latex agglutination and enzyme ininiunoassay) 
Table 1 Viral infections and atypical pathogens as causes of acute exacerbations of COP11 
~ _ _ _ _ _ _ _ _ _ _ _ _ _ _  _______ -~ 
Number Patients with 
of paticnts viral infection 
~~ 
Causativc viral or 
atypical pathogen 
Kademaker ct a1 [4] 
Mertens et al 151 
Hoepelman et dl 161 
Hoepelman et a1 I71 
50” 3 (6%) 
50 
71 
134 12 
Chlamydia pneuwotriae (4) 
A4ycoplarnia ynritrnoriiae ( 1 )  
Influenza A (2) 
Respiratory syiicytial-virus (1) 
LeXiorrcdla prieitniophila ( 1 )  
Chlamydia pneunroriiac ( 1 )  
Influenza A (2) 
LeXionella pnenmopphila (1) 
Chlamydia pneuimriiae (1) 
Chlamydia spp. ( 2 )  
Respiratory 5yiicytial-virus (1) 
Chlanrydia spp (2) 
Lqqiotiella pnruinophilu (1) 
Iiifluenza A/B ( 6 )  
I’arainflucnza (3) 
Respiratory syiicytial-viruy (3) 
dSerolo.q was performed in 50 patient4 out of 102 patients (for budget reasons). 
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excepted. A viral infection or an infection with one of 
the other pathogens was assumed in patients with at 
least a fourfold rise in antibody titers or an IgM 
response. 
Overall, evidence for a viral or atypical pathogen 
as a cause of infection was found in 28 patients (9.2%). 
A viral cause was found in 18 (5.9%). Positive serology 
for an atypical pathogen was documented 14 times in 
12 patients. Two patients had a viral and an atypical 
pathogen as the cause of their infection. In the largest 
of our studies, we could establish a correlation between 
eradication of the pathogen and clinical cure [7]. The 
rate of infection is somewhat lower than those reported 
in the past in unselected patients (type 1-3). It is 
assumed that in less severe cases (type 2/3) viruses play 
a more important role [3]. It  is remarkably lower (over 
40%) in comparison to a study by Nicholson et al [8] 
in younger patients (mean age 33 years) with asthma, 
who used new methods (polymerase chain reaction, 
PCR) to identify rhinoviruses and coronaviruses. A 
recent study by the Netherlands institute of primary 
health care (NIVEL) used this method to identify 
pathogens in influenza-like illness; in an additional 30% 
of patients, a pathogen could be identified (unpublished 
observations). We therefore conclude that the viral and 
atypical causes sought in our studies (excluding corona 
viruses and rhinoviruses) are uncommon causes of type 
1 exacerbations. However, a new study of the severest 
form of exacerbation (type 1) using P C R  as well as viral 
culture is needed. 
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The clinical microbiologist's contribution to audit, quality 
and guidelines 
Clin Microbiol Infect 1997; 3: 514-517 
In the UK, clinicians are obliged to take part in clinical 
audit, defined as the systematic critical review of the 
quality of medical care, including the procedures used 
for diagnosis and treatment, the use of resources and 
the resulting outcome. Pressures of cost containment 
and competition are intensifying the attention given 
to quality of care. Clinical microbiologists have an 
important role in the maintenance and improvement of 
the quality of patient care through their contributions 
to the diagnosis, management and prevention of 
infection. 
Historically, much emphasis has been placed on 
assurance of the quality of diagnostic activities within 
the clinical laboratory, particularly technical expertise. 
There are voluntary and compulsory arrangements to 
assess and assure the competence of the scientific and 
technical procedures carried out there. Some warn that 
there are too many [I]. Laboratories may run parallel 
internal quality assurance schemes [2-41. Periodic 
external review of a laboratory's proficiency is used 
as the basis for formal accreditation in many countries 
[5] but it covers only one aspect of the diagnostic cycle, 
albeit an important one. Accreditation and quality 
